In the second part of Dominic’s series on the neuroendocrine dysfunctions found in prolonged critical illness states and ME/CFS/FM he explores treatment options, and asks if returning the neuroendocrine system normality will require new treatment combinations.
- Neuroendocrine Dysfunctions in Prolonged Critical Illness: Relevance for Chronic Fatigue Syndrome ME/CFS and Fibromyalgia Pt. I
Section 2: Treatment
- Treatments with peripheral hormones
- Supplementing thyroid hormones in critical illness
- Supplementing thyroid hormones in ME/CFS and fibromyalgia
- Supplementing GH and IGF-1 in critical illness
- Supplementing GH and IGF-1 in ME/CFS and fibromyalgia
- Treatments with glucocorticoids in critical illness
- Supplementing with glucocorticoids in ME/CFS and fibromyalgia
- Treatments targeting the hypothalamus and pituitary
- Combination trials to reactivate secretion by the pituitary in prolonged critical illness
- Trials to reactivate GH secretion by the pituitary in fibromyalgia
- Reactivation of the HPA axis with corticotropin-releasing hormone (CRH)
- Hypothetical interventions to reset the HPA axis in ME/CFS (“bi-stability model”)
- Other treatments
- Traditional medicines
- Immune system modulation and anti-oxidants in prolonged critical illness
Researchers have tried to reverse neuroendocrine dysfunctions in prolonged critical ill patients, with the hope of reducing muscle wasting and mortality and aid overy. Similarly, researchers and clinicians have tried to remedy the depressed hormone status in ME/CFS.
The treatments largely differ depending on which neuroendocrine axes, and what parts of the neuroendocrine axes are being targeted. Many treatments involve supplementing depressed hormone levels directly, including thyroid hormone, IGF-1 and GH, and adrenal hormones (sub-section A). Other treatments target the dysfunction at the “central” level — i.e. the hypothalamus and/or the pituitary (sub-section B).
A. Treatments with peripheral hormones
The use of thyroid hormones, glucocorticoids (cortisol) and even GH and IGF-1 has a long history in medicine. They are mostly used to treat hypothyroidism, inflammation and growth failure, respectively. However, they have also been trialed and used to treat prolonged critical illness, ME/CFS and fibromyalgia.
Supplementing thyroid hormones in critical illness
Given the depressed levels of thyroid hormone activity found in critical illness, clinicians began, in the late 1970s, to suggest thyroid hormone supplementation in an attempt to increase survival rates (Carter et al., 1977; Brent et al., 1986 and DeGroot, 1999). This approach continues to be debated today (Davis, 2008; Kaptein et al., 2010; De Groot, 2015; Moura Neto et al., 2016; Breitzig et al. 2018). Results with thyroid supplementation have been mixed (see reviews in Farwell, 2008, and Fliers et al., 2015) but the dosage, type of supplement, and timing of treatment initiation could explain the discrepancy in outcomes (van den Berghe, 2014; van den Berghe, 2016).
Given the impaired conversion of T4 to T3 in prolonged critical illness, some researchers suggest using T3 supplementation (as opposed to T4 supplementation) (Biondi, 2014). Moreover, tests on rabbits have shown that thyroid hormone supplementation doses have to be higher than what the body naturally produces (i.e. supra-physiological) to achieve results (Debaveye, 2008). Many publications simply conclude that more studies on the effects of thyroid hormone supplementation in critical illness are required (Mancini et al., 2016).
Supplementing thyroid hormones in ME/CFS and fibromyalgia
Many stories exist of CFS/ME or fibromyalgia patients recovering by using thyroid hormones, particularly T3. I’ve listed some of the evidence and the approaches ME/CFS practitioners have used in my previous blog post. These approaches vary in the type of thyroid hormones (natural desiccated thyroid, synthetic T3 or T4, etc.), the dosage (supra-physiological vs. physiological), the complementary vitamin / mineral supplements, etc.
Several practitioners emphasize the importance of providing adrenal hormones in tandem with thyroid hormones to enable the body to cope with an increase in metabolic rate. In the absence of a standard protocol, patients are discussing these treatment variations in a plethora of online discussion forums.
I wonder why the supplementation of T3 can seemingly reverse uniform neuroendocrine suppression over several endocrine axes. Perhaps this is due to T3’s role in mediating the immune system (DeVito et al., 2011; Jara et al., 2017; Van der Spek et al., 2018) and the interactions between endocrine axes (see Annex).
Supplementing GH and IGF-1 in critical illness
The hormone IGF-1 has been tested and applied in critical illness for decades, with positive results in reducing catabolism (i.e. muscle and protein loss), recovery of gut mucosal function, tissue repair, control over inflammatory cytokines, decreased protein oxidation and increased glucose oxidation, etc. However, doses must be physiological (i.e. not higher than regularly produced by the body) in order to avoid side effects (see review by Elijah et al., 2011).
Some positive results have also occurred with administration of GH (or a synthetic version called rhGH) (reviews by Weekers and van den Berghe, 2004; and Elijah et al., 2011). However, a large scale double-blind randomized control study of rhGH infusions undertaken in 1999 resulted in increased mortality of patients (Takala et al., 1999). This led to the near cessation of the use of GH or rhGH in critical care. Since then other researchers have argued that that dosages were too high, thereby overwhelming the negative feedback loops (Weekers and van den Berghe, 2004).
Finally, some promising trials have also been done combining the administration of GH and IGF-1 in critical illness (Teng Chung and Hinds, 2006; Hammarqvist et al., 2010). Again, GH and IGF-1 have complementary roles in the balance between anabolic and catabolic activities.
Supplementing GH and IGF-1 in ME/CFS and fibromyalgia
A series of placebo-controlled studies demonstrated that GH injections over several months — in the form of physiological doses or doses adapted to increase IGF-1 to a specific level — reduced pain and improved quality of life scores in fibromyalgia patients in a number of studies (Bennett et al., 1998; Moorkens et al. 1998; Cuatrecasas et al., 2007; Cuatrecasas et al., 2012; and Cuatrecasas et al., 2014).
Treatments with glucocorticoids in critical illness
When clinicians determine that cortisol levels are low relative to the severity of the illness administration of large daily doses of hydrocortisone (200 – 300 mg) in patients during critical illness is quite common (see “critical illness-related corticosteroid insufficiency,” CIRCI) (Marik et al., 2007; Gheorghiță et al., 2015). Some researchers, however, argue that these high doses may be counterproductive because they further drive the negative feedback loop, resulting in “central” suppression of the axes (Teblick et al., 2019). Moreover, especially if administered for too long, large hydrocortisone doses heighten catabolic effects (see review in Boonen and van den Berghe, 2014a & 2014b).
Supplementing with glucocorticoids in ME/CFS and fibromyalgia
Several studies have documented that a low dose of hydrocortisone can benefit ME/CFS patients, notably reducing fatigue and disability scores (see reviews in Holtorf, 2008; and Tomas et al. 2013). Daily doses of 5 – 15 mg of hydrocortisone also apparently don’t suppress the HPA axis further (Demitrack et al., 1991; Cleare et al., 1999) and may even improve the otherwise “blunted” responses of the pituitary to the signal from the hypothalamus, i.e. to CRH (Cleare et al., 2001).
Researchers have also documented that somewhat higher doses of hydrocortisone (25 – 35 mg per day) lead to a moderate decrease in endogenous ACTH and cortisol production in chronic fatigue patients, via the negative feedback loop (Demitrack et al., 1991; McKenzie et al., 1998).
Combination of hormones
Given the complementarity of hormones and interactions between neuroendocrine axes, better results have often been achieved by giving several peripheral hormones at once. For example, a number of trials have indicated that adding GH and/or IGF-1 avoids the catabolism effects, such as protein wasting and osteoporosis, linked to high dose glucocorticoid treatments (Giustina et al., 1995; Oehri et al. 1996). Similarly, some ME/CFS practitioners prescribe a combination of hormones, including thyroid hormones, adrenal hormones and even gonadal hormones (c.f. Holtorf clinic; Teitelbaum 2007).
B. Treatments targeting the hypothalamus and pituitary
A number of critical illness researchers argue that instead of administering peripheral hormones, treatments should target the “central” level (i.e. the hypothalamus and pituitary). They have 3 main arguments:
- it has been shown that the neuroendocrine suppression during prolonged illness largely originates at the level of the hypothalamus (i.e. the hypothalamus is not sending the required signals to the pituitary);
- the pituitary and peripheral endocrine glands are, in fact, undamaged, and could operate normally if given the right signals (with perhaps the exception of the adrenals that experience atrophy).
- by targeting the process at the central level, the rest of the neuroendocrine axes are unaltered — specifically, the negative feedback loops and adaptive peripheral metabolism of hormones remain intact, thus preventing the risk of toxic over-dosages (van den Berghe, 2016).
In sum: These researchers argue that treatments targeting the hypothalamus and/or pituitary may be more effective and safer than administration of the peripheral active hormones. I will describe some of these treatment trials below.
Combination trials to reactivate secretion by the pituitary in prolonged critical illness
Van den Berghe and her team performed a series of fascinating treatment trials with critical ill patients who’d been in the intensive care units for several weeks. The various combinations of factors they used to stimulate the pituitary attempted to substitute for the signals which in normal conditions are produced largely by the hypothalamus (van den Berghe et al. 1998; van den Berghe et al. 1999; Van den Berghe et al. 2001; Van den Berghe et al., 2002).
Specifically, they administered combinations of TRH (which stimulates the pituitary to produce TSH, in turn stimulating the thyroid gland), GHRH (which stimulates the pituitary to produce GH), GHRP-2 (an artificial gherlin-like peptide which also stimulates the pituitary to produce GH), and GnRH (which stimulates the pituitary to produce LH and FSH, in turn stimulating the gonads). (See Table 3). Three major findings were produced.
FIrst, they showed that each of these factors can reactivate the secretion of the pituitary for the relevant neuroendocrine axis, while keeping the negative feedback loops on the pituitary intact, thus preventing overstimulation of the endocrine glands:
- The administration of GHRH or GHRP-2 reactivated the pulsatile secretion of GH by the pituitary, and the plasma concentrations of IGF-1 and IGFBP-3 increased. Interestingly, GHRP-2 had a much stronger effect than GHRH, suggesting that the inactivity of gherlin likely plays a key role in prolonged critical illness (van den Berghe, 2016).
- Similarly, when the team administered TRH, the pulsatile secretion of TSH by the pituitary was reactivated, and the plasma concentrations of the peripheral hormones T4 and T3 increased. However, reverse T3 (RT3) also increased. This is problematic because RT3 blocks thyroid hormone receptors at cell levels, contributing to low thyroid hormone activity (see my first and second blog posts).
- Likewise, the administration of GnRH to prolonged critically ill men increased pulsatile LH secretion by the pituitary.
Second, the team showed that when prolonged critically ill patients were treated with a combination of factors to normalize GH and TSH secretion by the pituitary (i.e GHRH or GHRP-2 in combination with TRH), reverse T3 did not increase! This suggests that the normalization of the HPS axis is necessary for inhibiting the production of the problematic RT3. The authors write: “coinfusing a GH secretagogue with TRH appeared to overcome the impaired peripheral conversion of thyroid hormones in the majority of critically ill patients.” This is likely because GH can deactivate the D3 enzyme which converts T4 into RT3 (Weekers and van de Berghe, 2004).
Finally, the team showed that the combination treatments immediately inhibited catabolism (i.e. tissue break-down) and promoted anabolism (i.e. tissue building), thus halting the muscle and fat wasting of patients with prolonged critical illness. This effect was absent when GHRP-2 was infused alone and strongest when GnRH was added to the mix in critically ill men (i.e. GHRP-2 + TRH + GnRH). The authors write:
Coadministration of GHRP-2, TRH and GnRH reactivated the GH, TSH and LH axes in prolonged critically ill men and evoked beneficial metabolic effects which were absent with GHRP-2 infusion alone and only partially present with GHRP-2 + TRH. These data underline the importance of correcting the multiple hormonal deficits in patients with prolonged critical illness to counteract the hypercatabolic state” (Van den Berghe et al., 2002).
I believe these results are potentially fascinating in terms of their relevance to ME/CFS and fibromyalgia. The treatments were only administered for 5 days for experimental purposes, and benefits ended a few days after the infusions were discontinued. The trials were never repeated, despite suggestions as late as 2016 that these successes should be further explored (van den Berhge, 2016).
Table 3: Treatment trials to reactivate the pituitary in prolonged critical illness (van den Berghe et al.)
|Target||Factors used to stimulate the pituitary||Results in prolonged critical illness|
|HPT Axis||TRH (which stimulates the pituitary to produce TSH, in turn stimulating the thyroid gland)||Reactivation of the HPT Axis|
Normalized TSH secretion by pituitary
Normalized T4 and T3 levels
|HPS Axis||GHRP-2 (artificial gherlin mimetic which stimulates the pituitary to produce GH)||Reactivation of the HPS Axis|
Normalized GH secretion by pituitary
Normalized IGF-1 and IGFBP-3 levels
|GHRH (which stimulates the pituitary to produce GH)||Lower pituitary reactivation response than with GHRP-2|
HPS + HPT Axes
|GHRP-2 + TRH||Reactivation of the HPS and HPT Axes|
Normalized GH secretion by pituitary
Normalized IGF-1 and IGFBP-3 levels
Normalized TSH secretion by pituitary
Normalized T4 and T3 levels
RT3 levels do not increase!
–> Inhibit catabolism and promote anabolism
HPS + HPT + HPG Axes
|GHRP-2 + TRH + GnRH (trialed with men)||Reactivation of the HPS, HPT and HPG Axes|
As above and also normalized LH secretion by the pituitary
-> Strongest beneficial metabolic effect
Trials to reactivate GH secretion by the pituitary in fibromyalgia
Recognizing that the secretion of GH by the pituitary is controlled by both stimulating (GHRF) and inhibiting (GHIF) signals from the hypothalamus, researchers tried to treat fibromyalgia patients with pyridostigmine (Mestinon), a drug that inactivates the inhibiting effect of GHIF.
Pyridostigmine did reverse the impaired GH response to exercise in fibromyalgia patients (Paiva et al.; 2002), but did not improve fibromyalgia symptoms (Jones et al.; 2008). This is consistent with van den Berghe et al.’s findings that the anabolic effects of GH only occur in combination with adequate action of the thyroid hormones (see Table 3).
Reactivation of the HPA axis with corticotropin-releasing hormone (CRH)
Complementary to the work of van den Berghe et al., researchers have suggested using CRH to reactivate the HPA axis in prolonged critical illness (Peeters et al., 2018a). (Recall that CRH is the signal from the hypothalamus that stimulates the pituitary to produce ACTH, in turn stimulating the adrenals).
These researchers argue that the suppressed HPA axis in prolonged critical illness (due to initial high levels of cortisol during the acute phase) is similar to the HPA axis suppression seen in patients on long-term glucocorticoid treatment. When the latter patients are withdrawn from their long-term treatment, clinicians apparently need to “reactivate” hypothalamic CRH secretion. The researchers thus suggest that providing CRH during critical illness could potentially allow the reactivation of ACTH synthesis by the pituitary, and thereby prevent the adrenal atrophy seen in the prolonged phase of the illness.
Hypothetical interventions to reset the HPA axis in ME/CFS (“bi-stability model”)
Recall the model describing ME/CFS patients as stuck in a “low-cortisol” HPA axis steady state .
Based on this model, researchers have proposed various fascinating interventions to move patients to the “normal-cortisol” HPA axis steady state.
Ben-Zavi et al. (2009) suggested that “a well-directed push given at the right moment may encourage the axis to reset under its own volition.” Specifically, they argue that artificially dropping cortisol levels even further than they already are in ME/CFS patients, should by taking advantage of the HPA axis’ negative feedback loop, increase ACTH secretion. According to their model, once ACTH levels exceed 30% of baseline levels, the HPA axis will naturally progress to the “normal-cortisol” HPA axis steady state and the treatment can be discontinued. I am not aware of any trials of this hypothesis.
Similarly, Sedghamiz et al. (2018) have suggested that an “externally applied stress” can serve to re-initiate proper HPA axis functioning. Specifically, this team has modeled the effect of blocking the glucocorticoid receptors (GRs). They argue that this intervention renders the low-cortisol “steady state” unstable – resulting in a return to the “normal-cortisol” steady state.
This is also basically the premise of the Cortene trials. I wonder whether — given the suppression of multiple neuroendocrine axes in ME/CFS — an intervention targeting just one axis will suffice. Perhaps, given the interactions between axes, the correction of the HPA axis might serve as a lever to also correct the other neuroendocrine axes.
Finally, based on the HPA bi-stability model, similar suggestions have been made for achieving remission from Gulf War Illness. Craddock et al. (2015) – who have included the immune system in their model – calculated that an initial inhibition of Th1 inflammatory cytokines (Th1Cyt), followed by a subsequent inhibition of GR function, would allow a robust return to a “normal-cortisol” steady state.
C. Other treatments
Given the many “central” and “peripheral” mechanisms modulating the function of the neuroendocrine axes — and the bi-directional relationship between the neuroendocrine axes and the immune system — many other potential forms of treatment for neuroendocrine dysfunctions exist. I list two further categories below.
Many traditional medicines may also help restore the function of the neuroendocrine axes, including Shilajit (a mineral rich plant deposit from India) and Myelophil (a mix of herbs from China) (Tomas et al., 2013).
In one experiment, researchers found that a combination of herbal extracts used in traditional chinese medicine to treat “Kidney Yang Deficiency Syndrome” attenuated the metabolic dysfunction induced by hydrocortisone injections in rats. Compared to controls, rats treated with the herbal extracts experienced less dysfunctions in energy metabolism, lipid metabolism, gut microbiota metabolism, biosynthesis of catecholamine (norepinephrine), and alanine metabolism (Zhao et al., 2013).
Immune system modulation and anti-oxidants in prolonged critical illness
See my previous blog: The Relevance of Research on Critical Illnesses for Chronic Fatigue Syndrome ME/CFS: A vicious cycle between cytokines, oxidative stress and thyroid hormones. Notably, recall that the thyroid hormone T3 also modulates the immune system.
Summary of Section 2: Trials to reverse neuroendocrine dysfunctions in prolonged critical illness and ME/CFS and fibromyalgia have a lot of similarities (see Table 4). Perhaps the most interesting lessons come from treatment combinations that target several neuroendocrine axes at once. These provide revelations about the interactions between the axes and have had important initial successes.
Table 4: Summary of treatments proposed and trialed to remedy neuroendocrine dysfunctions in ME/CFS and critical illness
|Neuroendocrine axes targeted||Treatments with peripheral hormones||Treatments targeting the hypothalamus and pituitary|
|HPT Axis (thyroid)||Prolonged critical illness:|
Supplementation w/ thyroid hormones
|Prolonged critical illness: Administration of TRH to reactivate pituitary secretion of TSH|
|ME/CFS and fibromyalgia: Supplementation w/ thyroid hormones (natural desiccated thyroid, T4, T3).||ME/CFS and fibromyalgia: none?|
|Prolonged critical illness:|
Supplementation with GH and IGF-1
|Prolonged critical illness: Administration of GHRH and GHRP-2 to reactivate pituitary secretion of GH|
|ME/CFS and fibromyalgia:|
Supplementation with GH and IGF-1
|ME/CFS and fibromyalgia: Drug to inactivate GH inhibiting hormone (GHIH)|
|HPA Axis (adrenals)||Prolonged critical illness: High dose hydrocortisone|
|Prolonged critical illness: Administration of CRH to stimulate pituitary ACTH secretion (proposed)|
|ME/CFS and fibromyalgia:|
Low dose hydrocortisone or other glucocorticoids
|ME/CFS and fibromyalgia:|
– Blocking of central glucocorticoids receptors (GRs) (Cortene Trials)
– Suppress cortisol levels to reactivate ACTH secretion (modelled)
– Inhibition of Th1 cytokines followed by inhibition of GRs (modelled for Gulf War Illness)
|HPG Axis (gonads)||Prolonged critical illness: none?||Prolonged critical illness: Administration of GnRH to stimulate pituitary release of LH (in men)|
|ME/CFS and fibromyalgia: as part of combined treatments (below)||ME/CFS and fibromyalgia: none?|
|Combination of axes|
|Prolonged critical illness: GH and IGF-1 in addition to hydrocortisone||Prolonged critical illness: TRH + GHRP-2 + GnRH (see Table 3. above).|
|ME/CFS and fibromyalgia:|
Thyroid hormone + adrenal hormones (+ gonadal hormones)
|ME/CFS and fibromyalgia: none?|
Irrespective of the nature of the original illness or trauma, multiple neuroendocrine axes are suppressed in the prolonged phase of critical illness, Similar patterns of neuroendocrine suppression have also been observed in ME/CFS and fibromyalgia.
The last decades have seen substantial advances in researchers’ understanding of the various “central” and “peripheral” mechanisms underlying critical illness, and the role cytokines and O&NS play in the persistence of neuroendocrine suppression during prolonged critical illness. These can undoubtedly inform our understanding of ME/CFS and fibromyalgia.
Similarly, the findings from ME/CFS and fibromyalgia specifically relating to the dysfunctions at the mitochondrial level — which are associated with the neuroendocrine alterations, inflammatory cytokines and O&NS — may be able to provide important complementary insights into critical illness. The sharing of knowledge and collaborations in these fields would likely serve to complete our understanding of both conditions.
Finally, a combined analysis of the treatments already tried for either prolonged critical illness or for ME/CFS might help identify potential approaches that could be trialed for one or the other of these conditions. The “millions missing” from ME/CFS, as well as the individuals hanging on for their lives in critical care units around the world, might find relief through treatment approaches that leverage the similarities between their conditions.
The Low T3 Series on Health Rising
- The Atypical Thyroid Issues in Chronic Fatigue Syndrome (ME/CFS), Plus a New Thyroid Subset?
- Pure T3 Thyroid and Stories of Recovery from Chronic Fatigue Syndrome (ME/CFS) and Fibromyalgia: An Overview.
The Critical Illness Series On Health Rising
- Neither dying, nor recovering”: Learning from ICUs to Solve ME/CFS and Fibromyalgia – A Synopsis (Nov. 2019)
- Neuroendocrine Dysfunctions in Prolonged Critical Illness: Relevance for Chronic Fatigue Syndrome ME/CFS and Fibromyalgia — Part I: Dysfunctions (Sep. 2019)
- Neuroendocrine Dysfunctions in Prolonged Critical illness: Relevance for Chronic Fatigue Syndrome ME/CFS and Fibromyalgia — Part II: Treatments (Sep. 2019)
- The Relevance of Research on Critical Illnesses for Chronic Fatigue Syndrome ME/CFS: A vicious cycle between cytokines, oxidative stress and thyroid hormones (July 2019)
After years of work it’s time to attempt what we’ve never been able to do before – get Congress to force the NIH to double its funding for ME/CFS. Support the historic bill to increase research funding, add new ME/CFS research centers, require the development of a strategic plan, etc.. It will take less than 5 minutes.